Mirati Therapeutics (NASDAQ:MRTX) Earns Sell Rating from Analysts at StockNews.com
StockNews.com started coverage on shares of Mirati Therapeutics (NASDAQ:MRTX – Free Report) in a report released on Tuesday. The brokerage issued a sell rating on the biotechnology company’s stock. Several other equities analysts also recently commented on MRTX. BMO Capital Markets upped their price objective on shares of Mirati Therapeutics from $31.00 to $72.00 and […]
More Stories
BP p.l.c. (LON:BP) Insider Acquires £372.24 in Stock
BP p.l.c. (LON:BP – Get Free Report) insider Murray Auchincloss acquired 88 shares of the firm’s stock in a transaction...
Barnwell Industries (NYSE:BRN) Earns Hold Rating from Analysts at StockNews.com
StockNews.com started coverage on shares of Barnwell Industries (NYSE:BRN – Free Report) in a research report released on Monday. The...
Express (NYSE:EXPR) Research Coverage Started at StockNews.com
StockNews.com assumed coverage on shares of Express (NYSE:EXPR – Free Report) in a report issued on Monday. The brokerage issued...
Amarin (NASDAQ:AMRN) Upgraded at StockNews.com
StockNews.com upgraded shares of Amarin (NASDAQ:AMRN – Free Report) from a sell rating to a hold rating in a report...
Cellectar Biosciences (NASDAQ:CLRB) Research Coverage Started at StockNews.com
StockNews.com began coverage on shares of Cellectar Biosciences (NASDAQ:CLRB – Free Report) in a research report report published on Monday...
Onsemi (NASDAQ:ON) Sets New 12-Month Low Following Analyst Downgrade
Onsemi (NASDAQ:ON – Get Free Report)’s share price reached a new 52-week low during trading on Tuesday after KeyCorp lowered...